Integrative analysis of SEC13: a prognostic predictor and immunotherapeutic target
- 2 February 2026
- journal article
- research article
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 28 (7) , 2931-2944
Abstract
Background The SEC13 is a multifaceted gene implicated in mTORC1 signaling regulation and the maintenance of genomic stability. Its function in cancer is complex, displaying potential oncogenic as well as potential tumor-suppressive roles across different malignancies. Therefore, this study aimed to investigate SEC13 expression, prognostic value, and its relationship with immune checkpoints across different cancer types. Methods Differential expression analysis, diagnostic analysis, and prognostic analysis were analyzed with The Cancer Genome Atlas and Human Protein Atlas database. The potential related genes were analyzed by utilizing Gene Expression Omnibus and clinical breast cancer samples. GO (Gene Ontology) and GSEA (Gene Set Enrichment Analysis) were used to elucidate the potential role of SEC13. TMB (tumor mutation burden), MSI (microsatellite instability), immune checkpoint, and immune cell infiltration were also analyzed to indicate its potential role in immune feature. To validate the functional impact of SEC13, its effects on cell proliferation and cell cycle distribution were assessed using CCK-8 assays and flow cytometry in MDA-MB-231 and MCF7 breast cancer cells following SEC13 knockdown. Results SEC13 was highly expressed in 14 tumor types and lowly expressed in 2 tumor types. High expression of SEC13 was associated with worse overall survival, disease-specific survival, and progression-free interval in breast cancer, liver hepatocellular carcinoma, and sarcoma. SEC13 expression was correlated with several co-expressed genes (e.g., MED8, RPN1) and was enriched in cell cycle pathway. Functionally, SEC13 knockdown was found to reduce the S-phase cell proportion and inhibit cell proliferation. In addition, SEC13 exhibited relationships with TMB and MSI, immune checkpoint, and immune cell infiltration. Conclusion This study underscores the significant expression differences and prognostic implications of SEC13 in various cancers, emphasizing its potential as a biomarker and therapeutic target.Keywords
Funding Information
- State Key Laboratory of Radiomedicine and Radiation Protection Fund (GZK12024008)
- Suzhou Health Young Key Talents“National Tutorial system” training project (Qngg 2023006)
- Suzhou Health Young Key Talents“National Tutorial system” training project (Qngg2024008)
- Preponderant clinic disipline group project (XKTJ-XK202009)
This publication has 31 references indexed in Scilit:
- Seize the engine: Emerging cell cycle targets in breast cancerClinical and Translational Medicine, 2024
- SPOP negatively regulates mTORC1 activity by ubiquitinating Sec13Cellular Signalling, 2024
- Intrinsically disordered region-mediated condensation of IFN-inducible SCOTIN/SHISA-5 inhibits ER-to-Golgi vesicle transportDevelopmental Cell, 2023
- M2 macrophage-derived extracellular vesicles augment immune evasion and development of colorectal cancer via a circRNA_CCDC66/microRNA-342-3p/metadherin axisCytotechnology, 2023
- The ever‐increasing importance of cancer as a leading cause of premature death worldwideCancer, 2021
- Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinomaJournal of Hepatology, 2020
- Prostate cancer cells modulate the differentiation of THP‐1 cells in response to etoposide and TLR agonists treatmentsCell Biology International, 2020
- Inhibition of PLD1 activity causes ER stress via regulation of COPII vesicle formationBiochemical and Biophysical Research Communications, 2017
- Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b studyThe Lancet Oncology, 2016
- Structure and Organization of Coat Proteins in the COPII CageCell, 2007